Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

386 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Antibody-mediated activation of the FGFR1/Klothoβ complex corrects metabolic dysfunction and alters food preference in obese humans.
Baruch A, Wong C, Chinn LW, Vaze A, Sonoda J, Gelzleichter T, Chen S, Lewin-Koh N, Morrow L, Dheerendra S, Boismenu R, Gutierrez J, Wakshull E, Wilson ME, Arora PS. Baruch A, et al. Among authors: morrow l. Proc Natl Acad Sci U S A. 2020 Nov 17;117(46):28992-29000. doi: 10.1073/pnas.2012073117. Epub 2020 Nov 2. Proc Natl Acad Sci U S A. 2020. PMID: 33139537 Free PMC article. Clinical Trial.
Bimagrumab improves body composition and insulin sensitivity in insulin-resistant individuals.
Garito T, Roubenoff R, Hompesch M, Morrow L, Gomez K, Rooks D, Meyers C, Buchsbaum MS, Neelakantham S, Swan T, Filosa LA, Laurent D, Petricoul O, Zakaria M. Garito T, et al. Among authors: morrow l. Diabetes Obes Metab. 2018 Jan;20(1):94-102. doi: 10.1111/dom.13042. Epub 2017 Aug 2. Diabetes Obes Metab. 2018. PMID: 28643356 Clinical Trial.
Effect of exogenously administered glucagon versus spontaneous endogenous counter-regulation on glycaemic recovery from insulin-induced hypoglycaemia in patients with type 2 diabetes treated with a novel glucokinase activator, AZD1656, and metformin.
Krentz AJ, Morrow L, Petersson M, Norjavaara E, Hompesch M. Krentz AJ, et al. Among authors: morrow l. Diabetes Obes Metab. 2014 Nov;16(11):1096-101. doi: 10.1111/dom.12323. Epub 2014 Jul 3. Diabetes Obes Metab. 2014. PMID: 24909093 Clinical Trial.
Subcutaneous Injection Depth Does Not Affect the Pharmacokinetics or Glucodynamics of Insulin Lispro in Normal Weight or Healthy Obese Subjects.
de la Peña A, Yeo KP, Linnebjerg H, Catton E, Reddy S, Brown-Augsburger P, Morrow L, Ignaut DA. de la Peña A, et al. Among authors: morrow l. J Diabetes Sci Technol. 2015 Jul;9(4):824-30. doi: 10.1177/1932296815573865. Epub 2015 Feb 19. J Diabetes Sci Technol. 2015. PMID: 25697717 Free PMC article. Clinical Trial.
Inhibition of fatty acid synthase with FT-4101 safely reduces hepatic de novo lipogenesis and steatosis in obese subjects with non-alcoholic fatty liver disease: Results from two early-phase randomized trials.
Beysen C, Schroeder P, Wu E, Brevard J, Ribadeneira M, Lu W, Dole K, O'Reilly T, Morrow L, Hompesch M, Hellerstein MK, Li K, Johansson L, Kelly PF. Beysen C, et al. Among authors: morrow l. Diabetes Obes Metab. 2021 Mar;23(3):700-710. doi: 10.1111/dom.14272. Epub 2020 Dec 21. Diabetes Obes Metab. 2021. PMID: 33289350 Free PMC article. Clinical Trial.
An exploratory, randomised, placebo-controlled, 14 day trial of the soluble guanylate cyclase stimulator praliciguat in participants with type 2 diabetes and hypertension.
Hanrahan JP, Seferovic JP, Wakefield JD, Wilson PJ, Chickering JG, Jung J, Carlson KE, Zimmer DP, Frelinger AL 3rd, Michelson AD, Morrow L, Hall M, Currie MG, Milne GT, Profy AT. Hanrahan JP, et al. Among authors: morrow l. Diabetologia. 2020 Apr;63(4):733-743. doi: 10.1007/s00125-019-05062-x. Epub 2019 Dec 19. Diabetologia. 2020. PMID: 31858186 Free PMC article. Clinical Trial.
386 results